A diversified portfolio of life science companies
Portfolio
Building a platform for long-term growth and impact
2024 annual report
Our purpose is to invest to extend and enhance human life
Watch video
Our team members are experts at what they do
Our people
A diversified portfolio of life science companies
Portfolio
Building a platform for long-term growth and impact
2024 annual report
1 / 6

Introducing Slingshot Therapeutics

| Video length 6:05

Introducing iOnctura

| Video length 5:52

Expansion of our senior team

| Video length 7:06

Launching Beacon Therapeutics

| Video length 7:36

Scaling for growth

| Video length 09:28

Ed Hodgkin and Magdalena Jonikas discuss OMass Series B

| Video length 7:43

Syncona CEO Martin Murphy discusses Clade Series A financing

| Video length 10:16

Anaveon doses first patient

| Video length 6:18

Introduction from Quell Therapeutics, CEO, Iain McGill

| Video length 5:38

Quell: the science and the unmet medical need for patients

| Video length 5:25

Syncona’s Martin Murphy and Freddie Dear: Quell Series A expansion

| Video length 4:25

Introducing Resolution Therapeutics

| Video length 11:28

Introduction to Purespring

| Video length 5:47

Syncona FY20: Martin Murphy discusses FY20 results

| Video length 6:15

Syncona FY20: Martin Murphy discusses the impact of COVID-19

| Video length 4:52

Syncona FY20: Martin Murphy discusses the outlook for Syncona

| Video length 2:53

Achilles doses first patient

| Video length 1:40

Gene Therapy explained

| Video length 3:11
1 / 6

Introducing Slingshot Therapeutics

Creating Yellowstone – Syncona’s launch team in action

A spotlight on our female leaders

Introducing iOnctura

Challenges continue but brighter days on the horizon

Navigating the biotech landscape: A journey from big pharma to innovative startups

Building a platform for the next generation of investors

Expansion of our senior team

Modality precision is the new precision in medicine

Taking a proactive approach to portfolio company sustainability

Launching Beacon Therapeutics

Leveraging the Syncona team for our next phase of growth

Good science must survive in challenging markets

Scaling for growth

Building a global leader in retinal gene therapy

Welcoming our first Windsor Fellowship intern to Syncona

Ed Hodgkin and Magdalena Jonikas discuss OMass Series B

Syncona CEO Martin Murphy discusses Clade Series A financing

1 / 6

iOnctura commences randomized Phase II study in metastatic uveal melanoma

Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer

OMass Therapeutics appoints Birgitte Volck as Non-Executive Director

Third Quarter Results FY2025

Spur Therapeutics Announces Positive Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Gene Therapy Candidate for Gaucher Disease, at WORLDSymposium™

Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease

Yellowstone Biosciences appoints Dr. Ita O’Kelly, previously Executive Director Product Management at Immunocore, as its Chief Operating Officer and a member of its Leadership Team

Beacon Therapeutics Granted FDA Regenerative Medicine Advanced Therapy (RMAT)

Anaveon appoints Dr. Richard Sachse as Chief Medical Officer

iOnctura reaches new clinical milestones in uveal melanoma

Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP)

Spur Therapeutics Announces Development Candidate in Parkinson’s Disease Gene Therapy Program

Resolution Therapeutics Announces Approval of Clinical Trial Application by AEMPS to Expand Phase 1/2 EMERALD Study of RTX001 into Spain

Quell Therapeutics Achieves Milestone for Type 1 Diabetes CAR-Treg Cell Therapy Program

OMass Therapeutics Appoints Professor Steven Charlton as Chief Scientific Officer

Slingshot Therapeutics launches with its first programme and £12.5 million to accelerate early-stage drug development

Search